Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, CA · Founded 2016 · CIK 0001787306 · Biotech · Public
Topical biologic therapies for immune-mediated skin diseases
arcutis.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $94M
- 1 Form D · Oct 2019
- 84 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 20 granted · 20 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $94,499,967 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2833 | Prelude Therapeutics | — | $97M |
| 2834 | Coriell Life Sciences, Inc. | — | $10M |
| 2835 | Tango Therapeutics | — | $95M |
| 2836 | Arcutis Biotherapeutics, Inc. | — | $94M |
| 2837 | OMNI BIO PHARMACEUTICAL, INC. | — | $28M |
| 2838 | ReAlta Life Sciences, Inc. | — | $94M |
| 2839 | Verve Therapeutics | — | $94M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Alexander AsamDirector
- Bhaskar ChaudhuriDirector
- Daniel EstesDirector
- Patrick HeronDirector
- Jonathan SilversteinDirector
- Ricky SunDirector
- Todd WatanabeDirector · Executive Officer
Patents
- Method for Reducing Side Effects from Administration of Phosphodiesterase-4 Inhibitorsapplication
- Method For Reducing Side Effects From Administration Of PHOSPHODIESTERASE-4 Inhibitorsgranted
- Method For Reducing Side Effects From Administration Of PHOSPHODIESTERASE-4 Inhibitorsgranted
- Pharmaceutical Compositions Of Spironolactone For Deep Dermal Drug Deliveryapplication
- Topical Roflumilast Aerosol Foamsapplication
- Self-preserving Topical Pharmaceutical Compositions Comprising Diethylene Glycol Monoethyl Etherapplication
- Topical Roflumilast Formulation Having Antifungal Propertiesapplication
- Pharmaceutical Compositions Of Spironolactone For Deep Dermal Drug Deliverygranted
- Topical Roflumilast Aerosol Foamsgranted
- Pharmaceutical Compositions Of Roflumilast In Aqueous Blends Of Water-miscible, Pharmaceutically Acceptable Solventsapplication
- Method For Reducing Side Effects From Administration Of PHOSPHODIESTERASE-4 Inhibitorsapplication
- Topical Roflumilast Formulation Having Improved Delivery And Plasma Half- Lifeapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.